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1. Introduction
Dysphagia  is  one  of  the  symptoms  in  patients  with  connective  tissue  diseases  (CTDs),
although it is not directly fatal and is a frequent complication. The frequency of esopha‐
geal  dysmotility  is  46-92%, 30-88%, 21-72%, and 50% in patients  with systemic sclerosis
(SSc),  mixed connective tissue disease (MCTD), systemic lupus erythematosis (SLE),  and
polymyositis/dermatomyositis (PM/DM), respectively [1-8]. While the cause of esophageal
dysfunction in patients with CTDs has been unclear, there are some reports that suggest
the  accumulation  of  extracellular  matrix,  neuropathy,  and autoantibody as  the  cause  of
esophageal dysfunction in patients with SSc [9-11]. On the other hand, there are few reports
relating to the cause of esophageal dysfunction in MCTD patients, despite its frequency.
Therefore, we examined the histopathological characteristics of esophageal lesions in MCTD
patients using 27 autopsy cases in Japan [12].
2. Histopathological analysis of esophagus in MCTD patients
2.1. Comparison between changes in the upper, middle, and lower portion of the esophagus.
To date, there have been studies demonstrating a high frequency of esophageal symptoms in
patients with MCTD [1-7,13] (Table 1). In our study, evidence of histological changes was found
in 25 of the 27 cases examined (91%). The differences may be due to differences in the method
of measurement. Esophageal dysmotility in MCTD patients is sometimes associated with the
dilatation of the distal esophagus (Figure 1). The main sites of esophageal change were
generally different between CTDs [8]. In patients with SSc and MCTD, the lower portion of
the esophagus changes histologically. Therefore, we examined 3 different regions of the
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esophagus, which we defined as follows: 1) upper, at the height of the ring around the cartilage
of the trachea; 2) middle, at the height of the bifurcation of the trachea; and 3) lower, just above
the esophago-cardiac junction. We compared histological changes for each portion. Of 12 cases
examined, 9 showed slight to severe changes in the lower portion, 3 showed slight to severe
changes in the middle portion, and none showed histopathological changes in the upper
portion. According to these results, the lower portion was involved in many cases of MCTD.
Figure 1. X-ray photograph of esophagus in MCTD patients.
Symptoms and dysmotility Actual number (Frequency) Reference
Abnormal esophageal motility 8/17 (47.1%) Bennett (1980) [1]
Esophageal symptoms 11/17 (64.7 %) Gutierrez (1982) [2]
• Heartburn 10/17 (58.8%)
• Regurgitation 6/17 (35.3%)
• Dysphagia 1/17 (5.9%)
Abnormal esophageal motility 14/17 (82.4%)
Esophageal symptoms Dantas (1985) [3]
• Dysphagia 6/12 (50%)
Abnormal esophageal motility 6/12 (50%)
Esophageal symptoms Marshall (1990) [4]
• Heartburn or regurgitation 29/61 (47.5%)
• Dysphagia 23/61 (37.7%)
Abnormal esophageal motility 21/35 (60.0%)
Esophageal symptoms 14/21 (66.6%) Doria (1991) [5]
• Heartburn 5/21 (23.8%)
Seminars in Dysphagia230
Symptoms and dysmotility Actual number (Frequency) Reference
• Regurgitation 5/21 (23.8%)
• Dysphagia 4/21(19.0%)
Abnormal esophageal motility 15/21 (71.4%)
Abnormal esophageal motility 15/17 (88.2%) Lapadula (1994) [6]
Abnormal esophageal motility 10/18 (55.6%) Rayes (2002) [7]
Esophageal symptoms Calerio (2006) [15]
• Heartburn 9/24 (37.5%)
• Dysphagia 18/24 (75%)
Abnormal esophageal motility
(cine-esophogram) 23/24 (95.8%)
Table 1. The frequency of esophageal involvement in patients with mixed connective tissue disease.
2.2. Comparison between changes in the inner circular muscular layer and outer
longitudinal muscular layer of the esophagus
As regards histological changes in the muscular layers, the inner circular muscular layer (IM)
exhibited more severe changes than the outer longitudinal muscular layer (OM) in 17 of 27
cases (63%). Eight cases (30%) showed similar changes. Two cases (7%) showed no pathological
changes in either IM or OM, and no cases (0%) showed more severe involvement of OM than
IM. Muscular dynamisms of IM and OM in esophageal motility are different. The IM is fairly
active and subject to greater stress than the OM [14]. Furthermore, esophageal regurgitation
often occurs and exerts direct effects on the IM, particularly in the lower esophagus. Thus the
IM in the lower portion may carry a larger physical stress than the OM. Therefore, more severe
histological changes may occur in the IM of the lower portion than in the OM.
2.3. Cellular and tissue change
In our study, the most striking change of the esophagus in MCTD was severe atrophy and
occasional disappearance of muscular fibers followed by fibrosis in muscular layer (Figure 2).
In contrast to smooth muscle, however, striated muscle of the upper esophageal portion
exhibited no marked changes. Similar histopathological changes occur in SSc [15,16]. In SSc
patients, histological features are also characterized by degeneration and disappearance of
smooth muscle cells with fibrosis, especially in the IM of the lower portion [17]. In our study,
ganglionic cells had not decreased in number and were not particularly atrophic except in
severely fibrotic areas. Vascular changes were also not overly severe in non-fibrotic regions,
although slight intimal thickening of small vessels was sporadically found in the fibrotic area.
The vein wall was injured and smooth muscle cell disruption and inflammatory cell invasion
were observed (Figure 3).
2.4. Pathogenesis of esophageal lesions
The factors that seem to be associated with esophageal dysfunction have been reported in some
studies, and include extracellular matrix degradation, disorder of blood circulation, and
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autoantibodies [10,18-20]. Our hypothesis was that autoantibodies are associated with the
pathogenesis of esophageal lesions. In immunohistochemical studies, anti-human IgG and
anti-C3 antibodies reacted positively with muscle tissues showing a myolytic appearance
accompanied by edema and inflammatory cell infiltration in MCTD autopsy case (Figures 4).
No IgM deposition was found (Figure 4). The reactivity of IgG extracted from sera of MCTD
patients against normal esophageal tissues was then assessed. Esophageal tissues used here
were non-cancerous parts taken intraoperatively from esophageal cancer patients without
specific immunological disorder. The IgG reacted with smooth muscle cells in the muscularis
mucosa, muscular layer and venous wall, the ganglion cells in Auerbach’s plexus, and
squamous epithelium of the esophagus (Figure 5), but did not react with striated muscle in
upper portion (Figure 5 A,B). IgG from MCTD patients also reacted with primary-cultured
Figure 2. Esophageal muscle degeneration and fibrosis in MCTD patients.
Figure 3. Vascular changes in the esophagus of MCTD patients.
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smooth muscle cells prepared from surgical specimens of esophagus (unpublished data)
(Figure 6). These results suggested that antibodies in the serum of patients with MCTD attack
smooth muscle tissues as well as other tissues of the esophagus.
Figure 4. Immunoglobulin and complement deposition in the muscular layer of the esophagus from MCTD patients.
Deposition of IgG (A), IgM (B), and complement C3 (C).
Figure 5. Reaction of IgG from MCTD patients with smooth muscles and other cells composing the esophagus. (A)
Esophageal smooth muscle tissue, (B) Higher magnification of esophageal smooth muscle tissue, (C) Medial smooth
muscle of the venous wall, (D) Ganglionic cell in Auerbach’s plexus, (E) Squamous epithelium of esophagus
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Figure 6. Reaction of IgG from MCTD patients with primary-cultured smooth muscle cells from esophagus.
3. Discussion
Histopathological features of the esophagus in SSc and MCTD patients are similar, but
muscular change in SSc is more progressive than in MCTD patients in our study. It has been
suggested that there is no association between manometric abnormality and cutaneous
symptoms in MCTD patients, and the characteristics of SSc are not always linked to esophageal
dysfunction [5]. The pathological mechanism of esophageal dysfunction in MCTD may be
similar but not always identical to that in SSc.
In patients with CTDs, autoimmune inflammation occurs in systemic organs such as kidney,
lung, skin and blood vessels, and so on. The gastrointestinal tract is also involved though the
histological features and grades are different from disease to disease even in the same CTD.
In CTDs, many kinds of autoantibodies may play an important role in causing the various
symptoms and diseases, whether they are fatal or not. These differ from disease to disease and
from tissue to tissue. We showed that IgG from MCTD patients reacts to various tissues such
as kidney and lung (unpublished data) (Figure 7). It is well known that pulmonary hyperten‐
sion is the fatal cause of MCTD. Anti-endothelial cell antibody (AECA) was identified in the
serum of MCTD patients, and was especially high in patients with pulmonary hypertension
[21]. We now examine the antigen of AECA in endothelial cells of small pulmonary vascular
vessels [22]. As for the autoantibody of MCTD against esophagus, our study revealed that IgG
extracted from MCTD patients showed a positive immunohistochemical reaction not only for
the smooth muscle cells of esophagus, but also for the ganglion cells in Auerbach’s plexus, the
vascular walls in esophageal muscular tissues, and squamous epithelium of the esophagus.
Dysphagia in MCTD and SSc patients may be one of the symptoms often occurring as an
autoimmune reaction.
The reason why the inner layer of the lower portion incurs more severe damage than other
portions has not been clarified. Esophageal manometry shows that this portion sustains more
intense mechanical stress in peristalsis than the outer layer or upper portions. Thus autoanti‐
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bodies, mechanical stress and regurgitation may induce the severe dysphagia in MCTD and
other CTDs.
Motility dysfunction is not a direct cause of death, but a strong association between esophageal
dysmotility and interstitial lung disease in patients with MCTD is indicated [23]. Therefore,
care must be taken with diagnosis.
Figure 7. Reaction of IgG from MCTD patients with various tissues. (A) kidney, (B) lung
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